Saturday 17 October 2026
Export INCR’s income statement to Excel — free account
InterCure Ltd.
INCR Healthcare Drug Manufacturers Specialty & Generic
InterCure Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $78.5 million, up 18.4% from fiscal 2024.
4.66
0.01
+0.22%
Follow INCR
InterCure Ltd. (INCR) P/E ratio
As of 16 October 2026, InterCure Ltd. (INCR) trades at a P/E ratio of 8.8×. Over the past ten years it has ranged from 5.7× (March 2023) to 291× (April 2021); the current reading is higher than 9% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 19.2× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 8.6× | (42.77%) |
| FY2024 | 15.0× | 21.93% |
| FY2023 | 12.3× | 10.99% |
| FY2022 | 11.1× | (94.61%) |
| FY2021 | 206× | 304.48% |
| FY2020 | 50.9× | 0.00% |
| FY2019 | 50.9× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 16.1× | 57.38% |
| Mar 2023 | 10.2× | (8.06%) |
| Dec 2022 | 11.1× | (34.55%) |
| Sep 2022 | 17.0× | (39.85%) |
| 9 more quarters | Free account |
Against its own ten years
Low 5.7×
High 291×
Ten-year median
15.4×
Current reading's percentile
9
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RMTI Rockwell Medical, Inc. compare | n/m |
| CTOR Citius Oncology, Inc. compare | n/m |
| SCYX SCYNEXIS, Inc. compare | n/m |
| IXHL Incannex Healthcare Inc. compare | n/m |
| CLVR Clever Leaves Holdings Inc. compare | n/m |
| TLPH Talphera, Inc. compare | n/m |
| CPHI China Pharma Holdings, Inc. compare | n/m |
| INCR InterCure Ltd. | 8.8× |
| ZYBT Zhengye Biotechnology Holding Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)